This Is What We’re Talking About!
Find out why one Biotechnology Stock has begun to captivate a growing audience. We’re talking BIG BREAKING NEWS, emerging pipeline therapies, and more!
FDA Approves a Therapy Option to Help Treat Sickle Cell Disease
Global Blood Therapeutics, Inc. (GBT) was granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for voxelotor for the treatment of sickle cell disease (SCD). Voxelotor, previously called GBT440, is in development as a disease-modifying therapy and previously received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for the same indication. Two years ago, it was granted orphan drug designation from the FDA.
GE Healthcare Creates a Joint Venture with Roche to Develop Precision Medicine Oncology Platform
GE Healthcare and pharmaceutical giant Roche announced a partnership to collectively develop and co-market digital clinical decision support solutions. Oncology care and treatments are emerging as among the most popular applications of precision medicine thus far. Late last year, for instance, the U.S. Food and Drug Administration approved and the Centers for Medicare and Medicaid Services said it would reimburse doctors for using a breakthrough test to pinpoint cancer biomarkers.